文献速递MDS 与骨髓增殖性肿瘤白血病贫血与红细胞疾病

SF3B1突变髓系肿瘤183例突变特征与预后分析

[Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性队列研究分析183例伴SF3B1突变髓系肿瘤患者,采用高通量测序检测52种常见基因突变。不同亚型突变谱和预后不同:MDS基因突变数低于MDS/MPN和AML;SF3B1 VAF<10%者血红蛋白更高、环状铁粒幼红细胞比例更低;MDS-SF3B1和MDS/MPN的5年总生存率优于AML。

要点

  • SF3B1突变主要位于HEAT结构域第581~933位氨基酸,共检测到31种突变类型。
  • MDS患者中位基因突变数低于MDS/MPN和AML患者,差异均有统计学意义。
  • MDS-SF3B1和MDS/MPN的5年总生存率优于AML患者。

核心结论

  • SF3B1突变髓系肿瘤不同亚型患者具有不同的突变谱及预后。

研究设计与样本

  • 回顾性队列研究,纳入2016年10月至2024年12月苏州大学附属第一医院诊治的183例伴SF3B1突变的髓系肿瘤患者。
  • 采用高通量测序检测髓系肿瘤常见52种基因突变。

主要发现

  • 共检测到31种SF3B1突变类型,突变位点主要分布在HEAT结构域第581~933位氨基酸。
  • MDS患者中位基因突变数[2(1~7)]低于MDS/MPN[4(1~9)]和AML[3(1~9)],P值均<0.001。
  • 在克隆性造血和原始细胞比例<5%的MDS患者中,SF3B1突变VAF<10%者中位HGB高于VAF≥10%者(95 g/L对76 g/L,P=0.002)。
  • SF3B1突变VAF<10%者中位环状铁粒幼红细胞比例低于VAF≥10%者(3%对41%,P<0.001)。
  • MDS/MPN患者JAK2 V617F和RUNX1突变发生率高于MDS患者(22.2%对1.2%,P=0.001;33.3%对6.6%,P=0.002);AML患者RUNX1和RAS通路相关基因突变发生率均高于MDS患者(24.2%对6.6%,P=0.008;66.7%对3.8%,P<0.001)。

关键数值与推荐

  • 在MDS和MDS/MPN中,RUNX1突变阳性患者较野生型具有更高的AML进展风险(P<0.001)。
  • MDS-SF3B1和MDS/MPN的5年总生存率分别为91.6%和79.9%,优于AML的63.8%(P值分别为<0.001和0.033)。

临床怎么用

  • 对SF3B1突变髓系肿瘤应结合亚型、SF3B1 VAF及共存突变(如RUNX1、JAK2 V617F、RAS通路)进行风险分层。
  • SF3B1突变VAF<10%且原始细胞<5%的MDS患者血红蛋白水平较高、环状铁粒幼红细胞比例较低。

局限性

  • 本文为单中心回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the mutational characteristics and prognosis of patients with myeloid neoplasms and SF3B1 mutations. Methods: This retrospective cohort study analyzed clinical data from 183 patients with myeloid neoplasms and SF3B1 mutations diagnosed at the First Affiliated Hospital of Soochow University from October 2016 to December 2024. High-throughput sequencing was used to detect mutations in 52 common genes associated with myeloid neoplasms, and the patients' mutational characteristics were examined. Results: A total of 31 types of SF3B1 mutations were detected in the present study. SF3B1 mutations mainly occurred within the HEAT domain, spanning amino acids 581 to 933. The median number of gene mutations in patients with myelodysplastic neoplasms (MDS) [2 (1-7) ] was lower than that in patients with SF3B1-mutated myelodysplastic/myeloproliferative neoplasms (MDS/MPN) [4 (1-9) ] and acute myeloid leukemia (AML) [3 (1-9) ], with all differences being significant (all P<0.001). Among patients with clonal hematopoiesis and MDS with <5% blasts, those with an SF3B1 mutational variant allele frequency (VAF) of <10% had higher median HGB levels than those with an SF3B1 mutation VAF of ≥10% (95 g/L vs 76 g/L, P=0.002). Patients with an SF3B1 mutation VAF of <10% had a lower median percentage of ring sideroblasts than those with an SF3B1 mutation VAF of ≥10% (3% vs 41%, P<0.001). Furthermore, the incidence of JAK2 V617F mutations was higher in the MDS/MPN patients than in the MDS patients (22.2% vs 1.2%, P=0.001), as was the incidence of RUNX1 mutations (33.3% vs 6.6%, P=0.002). The incidence of RUNX1 mutation was higher in AML patients than in MDS patients (24.2% vs 6.6%, P=0.008), as was the RAS family gene mutations (66.7% vs 3.8%, P<0.001). In MDS and MDS/MPN, patients with RUNX1 mutations had a higher risk of progression to AML than those without such a mutation (P<0.001). Patients with MDS-SF3B1 (91.6%) and MDS/MPN (79.9%) demonstrated better 5-year overall survival than those with AML (63.8%) (P< 0.001 and P=0.033, respectively). Conclusion: Patients with different subtypes of SF3B1-mutated myeloid neoplasms exhibit distinct mutational profiles and prognoses. 目的: 分析伴SF3B1突变髓系肿瘤患者的突变特征及预后。 方法: 本回顾性队列研究收集2016年10月至2024年12月苏州大学附属第一医院诊治的183例伴SF3B1突变的髓系肿瘤患者的临床资料,采用高通量测序检测髓系肿瘤常见52种基因突变,分析患者的突变特征及预后。 结果: 在本研究病例中,共计检测到31种SF3B1突变类型,突变位点主要分布在SF3B1基因HEAT结构域第581~933位氨基酸。骨髓增生异常肿瘤(MDS)患者中位基因突变数[2(1~7)]低于伴SF3B1突变的骨髓增生异常肿瘤/骨髓增殖性肿瘤(MDS/MPN)患者[4(1~9)]和急性髓系白血病(AML)患者[3(1~9)],差异均有统计学意义(P值均<0.001)。在克隆性造血和原始细胞比例<5%的MDS患者中,SF3B1突变变异等位基因频率(VAF)<10%的患者中位HGB水平高于SF3B1突变VAF≥10%的患者(95 g/L对76 g/L,P=0.002)。并且,SF3B1突变VAF<10%的患者中位环状铁粒幼红细胞比例低于SF3B1突变VAF≥10%的患者(3%对41%,P<0.001)。此外,MDS/MPN患者中JAK2 V617F突变和RUNX1突变的发生率高于MDS患者(22.2%对1.2%,P=0.001;33.3%对6.6%,P=0.002)。AML患者中RUNX1和RAS通路相关基因突变发生率均高于MDS患者(24.2%对6.6%,P=0.008;66.7%对3.8%,P<0.001)。在MDS和MDS/MPN中,RUNX1突变阳性患者较RUNX1突变野生型患者具有更高的AML进展风险(P<0.001)。MDS-SF3B1(91.6%)和MDS/MPN(79.9%)患者的5年总生存率优于AML(63.8%)患者(P值分别为<0.001和0.033)。 结论: SF3B1突变髓系肿瘤不同亚型患者具有不同的突变谱及预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang HM, Wu N, Jiang AR, et al. [Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851180. doi:10.3760/cma.j.cn121090-20260303-00116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。